RIGL Rigel Pharmaceuticals Inc

Price (delayed)

$30.33

Market cap

$561.17M

P/E Ratio

1.5

Dividend/share

N/A

EPS

$20.23

Enterprise value

$582.48M

?
Relative Growth: Rel. Growth: 76
Relative Strength: Rel. Strength: 36
Relative Valuation: Rel. Valuation: 98
Relative Profitability: Rel. Profitability: 99

Rigel Pharmaceuticals, Inc., is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with hematologic disorders, cancer and rare ...

Highlights
The company's gross profit has surged by 54% YoY
Rigel Pharmaceuticals's revenue has increased by 48% YoY

Key stats

What are the main financial stats of RIGL

RIGL stock price

How has the Rigel Pharmaceuticals stock price performed over time
Intraday
0.1%
1 week
0.93%
1 month
2.67%
1 year
47.66%
YTD
-29.19%
QTD
12.17%

Financial performance

How have Rigel Pharmaceuticals's revenue and profit performed over time
Revenue
$299.77M
Gross profit
$279.95M
Operating income
$124.58M
Net income
$364.23M
Gross margin
93.4%
Net margin
121.5%
RIGL's operating income has surged by 184% year-on-year
The operating margin has soared by 93% YoY but it has contracted by 2.3% from the previous quarter
The company's gross profit has surged by 54% YoY
Rigel Pharmaceuticals's revenue has increased by 48% YoY

Price vs fundamentals

How does RIGL's price correlate with its fundamentals

Growth

What is Rigel Pharmaceuticals's growth rate over time

Valuation

What is Rigel Pharmaceuticals stock price valuation
P/E
1.5
P/B
1.4
P/S
1.86
EV/EBIT
4.52
EV/EBITDA
4.44
EV/Sales
1.94
The stock's price to earnings (P/E) is 46% less than its last 4 quarters average of 2.8
The price to book (P/B) is 52% less than the last 4 quarters average of 2.9
RIGL's equity is up by 2.2% from the previous quarter
Rigel Pharmaceuticals's revenue has increased by 48% YoY
The stock's price to sales (P/S) is 23% less than its 5-year quarterly average of 2.4 but 3.3% more than its last 4 quarters average of 1.8

Efficiency

How efficient is Rigel Pharmaceuticals business performance
Rigel Pharmaceuticals's return on sales has surged by 89% YoY but it has decreased by 2.1% QoQ
The ROE has declined by 39% since the previous quarter
RIGL's return on invested capital is down by 30% since the previous quarter and by 18% year-on-year
The return on assets has declined by 23% since the previous quarter

Dividends

What is RIGL's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for RIGL.

Financial health

How did Rigel Pharmaceuticals financials performed over time
Rigel Pharmaceuticals's total assets has soared by 187% YoY
The total liabilities has contracted by 33% YoY and by 14% from the previous quarter
RIGL's debt is 89% lower than its equity
RIGL's debt to equity has shrunk by 97% YoY and by 21% QoQ
RIGL's debt is down by 25% YoY and by 14% QoQ

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.